BioCentury
ARTICLE | Clinical News

Lamazym: Phase II data

January 7, 2013 8:00 AM UTC

Data from a 12-month, open-label, Danish Phase IIa trial and a 6-month follow-up Phase IIb trial in 9 patients with alpha-mannosidosis showed that once-weekly IV Lamazym significantly improved the 3MS...